Differential effects of adiponectin in osteoblast-like cells

References

• Laet CD, Kanis JA, Odén A, Johanson H, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 2005;16:1330–8
   PubMed Web of Science ®Google Scholar
• Pacheco-Pantoja EL, Ranganath LR, Gallagher JA, et al. Receptors and effects of gut hormones in three osteoblastic cell lines. BMC Physiol 2011;11:1–14
   PubMedGoogle Scholar
• Talbott SM, Rothkopf MM, Shapses SA. Dietary restriction of energy and calcium alters bone turnover and density in younger and older female rats. J Nutr 1998;128:640–5
   PubMed Web of Science ®Google Scholar
• Zeni SN, Ortela Soler CR, Lazzari A, et al. Interrelationship between bone turnover markers and dietary calcium intake in pregnant women: a longitudinal study. Bone 2003;33:606–13
   PubMed Web of Science ®Google Scholar
• Henriksen DB, Alexandersen P, Bjarnason NH, et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 2003;18:2180–9
   PubMed Web of Science ®Google Scholar
• Seibel MJ. Bone turnover in nutrition-related disorders. Wien Med Wochenschr 2007;157:582–8
   PubMedGoogle Scholar
• Revilla M, Villa LF, Sánchez-Atrio A, et al. Influence of body mass index on the age-related slope of total and regional bone mineral content. Calcif Tissue Int 1997;61:134–8
   PubMed Web of Science ®Google Scholar
• Ricci TA, Heymsfield SB, Pierson R Jr, et al. Moderate energy restriction increases bone resorption in obese postmenopausal women. Am J Clin Nutr 2001;73:347–52
   PubMed Web of Science ®Google Scholar
• Napoli N, Faccio R, Shrestha V, et al. Estrogen metabolism modulates bone density in men. Calcif Tissue Int 2007;80:227–32
   PubMed Web of Science ®Google Scholar
• Sadie-Van Gijsen H, Crowther NJ, Hough FS, Ferris WF. The interrelationship between bone and fat: from cellular see-saw to endocrine reciprocity. Cell Mol Life Sci 2012;70:2331–49
   PubMed Web of Science ®Google Scholar
• Konukoglu D, Serin O, Ercan M. Plasma leptin levels in obese and non-obese postmenopausal women before and after hormone replacement therapy. Maturitas 2000;36:203–7
   PubMed Web of Science ®Google Scholar
• Elefteriou F, Ahn JD, Takeda S, et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 2005;434:514–20
   PubMed Web of Science ®Google Scholar
• Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930–5
   PubMed Web of Science ®Google Scholar
• Díez JJ, Iglesias P. The role of the novel adipocyte-derived protein adiponectin in human disease: an update. Mini Rev Med Chem 2010;10:856–69
   PubMed Web of Science ®Google Scholar
• Berner HS, Lyngstadaas SP, Spahr A, et al. Adiponectin and its receptors are expressed in bone-forming cells. Bone 2004;35:842–9
   PubMed Web of Science ®Google Scholar
• Luo XH, Guo LJ, Yuan LQ, et al. Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res 2005;309:99–109
   PubMed Web of Science ®Google Scholar
• Luo XH, Guo LJ, Xie H, et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res 2006;21:1648–56
   PubMed Web of Science ®Google Scholar
• Oshima K, Nampei A, Matsuda M, et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun 2005;331:520–6
   PubMed Web of Science ®Google Scholar
• Luo XH, Zhao LL, Yuan LQ, et al. Development of arterial calcification in adiponectin-deficient mice: adiponectin regulates arterial calcification. J Bone Miner Res 2009;24:1461–8
   PubMed Web of Science ®Google Scholar
• Maahs DM, Ogden LG, Kinney GL, et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 2005;111:747–53
   PubMed Web of Science ®Google Scholar
• Tu Q, Zhang J, Dong LQ, et al. Adiponectin inhibits osteoclastogenesis and bone resorption via APPL1-mediated suppression of Akt1. J Biol Chem 2011;286:12542–53
   PubMed Web of Science ®Google Scholar
• Moss DW. Physicochemical and pathophysiological factors in the release of membrane-bound alkaline phosphatase from cells. Clin Chim Acta 1997;257:133–40
   PubMed Web of Science ®Google Scholar
• Peirson SN, Butler JN, Foster RG. Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis. Nucleic Acids Res 2003;31:1–20
   PubMed Web of Science ®Google Scholar
• Swarbrick MM, Havel PJ. Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord 2008;6:87–102
   PubMedGoogle Scholar
• Tietz NW, Burtis CA, Duncan P, et al. A reference method for measurement of alkaline phosphatase activity in human serum. Clin Chem 1983;29:751–61
   PubMed Web of Science ®Google Scholar
• Bowler WB, Dixon CJ, Halleux C, et al. Signaling in human osteoblasts by extracellular nucleotides. Their weak induction of the c-fos proto-oncogene via Ca2+ mobilization is strongly potentiated by a parathyroid hormone/cAMP-dependent protein kinase pathway independently of mitogen-activated protein kinase. J Biol Chem 1999;274:14315–24
   PubMed Web of Science ®Google Scholar
• Chen TH, Chen L, Hsieh MS, et al. Evidence for a protective role for adiponectin in osteoarthritis. Biochim Biophys Acta 2006;1762:711–18
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003;423:762–9
   PubMed Web of Science ®Google Scholar
• Ohashi K, Ouchi N, Sato K, et al. Adiponectin promotes revascularization of ischemic muscle through a cyclooxygenase 2-dependent mechanism. Mol Cell Biol 2009;29:3487–99
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Ouchi N, Kihara S, et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 2004;94:e27–31
   PubMed Web of Science ®Google Scholar
• Ross PD, Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res 1998;13:297–302
   PubMed Web of Science ®Google Scholar
• Kress BC, Mizrahi IA, Armour KW, et al. Use of bone alkaline phosphatase to monitor alendronate therapy in individual postmenopausal osteoporotic women. Clin Chem 1999;45:1009–17
   PubMed Web of Science ®Google Scholar
• Burshell AL, Möricke R, Correa-Rotter R, et al. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone 2010;46:935–9
   PubMed Web of Science ®Google Scholar
• Avbersek-Luznik I, Gmeiner Stopar T, Marc J. Activity or mass concentration of bone-specific alkaline phosphatase as a marker of bone formation. Clin Chem Lab Med 2007;45:1014–18
   PubMed Web of Science ®Google Scholar
• Shinoda Y, Yamaguchi M, Ogata N, et al. Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem 2006;99:196–208
   PubMed Web of Science ®Google Scholar
• Körner A, Wabitsch M, Seidel B, et al. Adiponectin expression in humans is dependent on differentiation of adipocytes and down-regulated by humoral serum components of high molecular weight. Biochem Biophys Res Commun 2005;337:540–50
   PubMed Web of Science ®Google Scholar
• Wang Y, Lam JB, Lam KSL, et al. Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 2006;66:11462–70
   PubMed Web of Science ®Google Scholar
• Gregory P, Kraemer E, Zürcher G, et al. GPI-specific phospholipase D (GPI-PLD) is expressed during mouse development and is localized to the extracellular matrix of the developing mouse skeleton. Bone 2005;37:139–47
   PubMed Web of Science ®Google Scholar
• Deeg MA, Bowen RF, Williams MD, et al. Increased expression of GPI-specific phospholipase D in mouse models of type 1 diabetes. Am J Physiol Endocrinol Metab 2001;281:E147–54
   Web of Science ®Google Scholar
• Schofield JN, Stephens JW, Hurel SJ, et al. Insulin reduces serum glycosylphosphatidylinositol phospholipase D levels in human type I diabetic patients and streptozotocin diabetic rats. Mol Genet Metab 2002;75:154–61
   PubMed Web of Science ®Google Scholar
• Raikwar NS, Bowen-Deeg RF, Du XS, et al. Glycosylphosphatidylinositol-specific phospholipase D improves glucose tolerance. Metabolism 2010;59:1413–20
   PubMed Web of Science ®Google Scholar
• Xing Y, Gu Y, Xu LC, et al. Effects of membrane cholesterol depletion and GPI-anchored protein reduction on osteoblastic mechanotransduction. J Cell Physiol 2011;226:2350–9
   PubMed Web of Science ®Google Scholar
• Deeg MA, Raikwar NS, Johnson C, Williams, CD. Statin therapy reduces serum levels of glycosylphosphatidylinositol-specific phospholipase D. Trans Res 2007;150:153–7
   Google Scholar
• Ding PY, Hsu PF, Lu TM. Statin therapy on insulin resistance and plasma level of adiponectin in non-diabetic, hypercholesterolemic patients. Acta Cardiol Sin 2009;25:183–189
   Web of Science ®Google Scholar
• Zhang Y, Bradley AD, Wang D, Reinhardt RA. Statins, bone metabolism and treatment of bone catabolic diseases. Pharmacol Res 2014; Epub ahead of print
   Google Scholar
• Stein GS, Lian JB. Molecular mechanisms mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype. Endocr Rev 1993;14:424–42
   PubMed Web of Science ®Google Scholar
• Sodi R, Hazell MJ, Durham BH, et al. The circulating concentration and ratio of total and high molecular weight adiponectin in post-menopausal women with and without osteoporosis and its association with body mass index and biochemical markers of bone metabolism. Clin Biochem 2009;42:1375–80
   PubMed Web of Science ®Google Scholar
• Lewinson D, Rachmiel A, Rihani-Bisharat S, et al. Stimulation of Fos- and Jun-related genes during distraction osteogenesis. J Histochem Cytochem 2003;51:1161–8
   PubMed Web of Science ®Google Scholar
• Gallagher JA. ATP P2 receptors and regulation of bone effector cells. J Musculoskelet Neuronal Interact 2004;4:125–7
   PubMedGoogle Scholar
• Gartland A, Orriss IR, Rumney RMH, et al. Purinergic signalling in osteoblasts. Front Biosci 2012;17:16–29
   Web of Science ®Google Scholar
• Miller M, Cho JY, Pham A, et al. Adiponectin and functional adiponectin receptor 1 are expressed by airway epithelial cells in chronic obstructive pulmonary disease. J Immunol 2009;182:684–91
   Google Scholar
• English PJ, Coughlin SR, Hayden K, et al. Plasma adiponectin increases postprandially in obese, but not in lean, subjects. Obes Res 2003;11:839–44
   PubMedGoogle Scholar
• Doran AC, Meller N, Cutchins A, et al. The helix-loop-helix factors Id3 and E47 are novel regulators of adiponectin. Circ Res 2008;103:624–34
   PubMed Web of Science ®Google Scholar